Bioequivalence Study of Bosentan 125 mg Tablets Immediate Release (IR) Versus Tracleer® 125 mg Tablets IR In Healthy Subjects

Bioequivalence Clinical Trial

Official title:

Two-way Crossover, Open-label, Single-dose, Bioequivalence Study of Bosentan (LLC "GEROPHARM", Russia) 125 mg Tablets Immediate Release (IR )Versus Tracleer® (Actelion Pharmaceuticals Ltd., Switzerland) 125 mg Tablets IR in Normal Healthy Subjects Under Fasting Conditions

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04101370
• Other study ID #: BOZ-501
• Status: Completed
• Phase: Phase 1
• Start date: May 24, 2018
• Est. completion date: June 20, 2018

Study information

• Verified date: March 2019
• Source: Geropharm
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Bioequivalence Study of 2 formulation of bosentan (Bosentan GEROPHARM vers. Tracleer® Actelion)

Description:

Study to evaluate the bioequivalence of orally administered bosentan preparations, immediate release tablets, 125 mg in normal healthy subjects under fasting conditions

Recruitment information / eligibility

• Status: Completed
• Enrollment: 64
• Est. completion date: June 20, 2018
• Est. primary completion date: June 20, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• Signed informed consent form.

• Healthy male aged 18 to 45 years.

• Verified diagnosis is "healthy" according to data Standard clinical, laboratory and Instrumental methods of examination.

• Have a body mass index between 18,5 and 30 kg/m2.

• Subjects must use, with their partner, methods of highly effective contraception throughout the study and 30 days after the end of study.

• Ability to keep fasting state for at least 14 hours.

• Consent and ability to respect the schedule of visits and the points of the Protocol.

Exclusion Criteria:

• History of serious allergic problems/events.

• Medicinal intolerance.

• Any acute and chronic diseases of the cardiovascular system, cardiovascular, bronchopulmonary, neuroendocrine systems, as well as diseases of the gastrointestinal tract, liver, kidneys, blood.

• Psychiatric disorders, history of epilepsy and seizures.

• Acute infectious diseases in less than 4 weeks before the start of the study.

• Subjects who have taken medication 2 weeks preceding before the study.

• Subjects who have taken any drugs known effects on hemodynamics or to induce or inhibit hepatic drug metabolism within 30 days prior to administration of the study medication (examples of inducers: barbiturates, omeprazole, etc.).

• Donation of plasma (450 mL or more) within 2 month prior to administration of the study medication.

• History of significant alcohol or drugs abuse or any indication of the regular use of more than 10 units of alcohol per week (1 Unit = 200 mL of wine or 500 mL of beer or 50 mL of alcohol 40%).

• Smokers.

• Participation in other clinical training is less than than for 3 months before the study.

• Lack of signed informed consent form.

• 10% deviation from references in lab tests.

• Positive testing for alcohol, drugs.

• Dehydration due to diarrhea, vomiting, or other causes within the last 24 hours before the start of the study.

• Any diet (vegetarian, etc.) extreme physical exercise, night shift work.

• Heart rate below 60 or above 80 beats per minute.

• Systolic blood pressure less than 110 mm Hg or more than 139 mm Hg.

• Diastolic blood pressure less than 60 mm Hg or more than 89 mm Hg.

• Volunteers, for Investigator opinion, who can not understand and evaluate the information about this study.

Related Conditions & MeSH terms

• Bioequivalence

Intervention

Drug:
• Bosentan 125 mg
Single administered dose of Bosentan (125 mg tablet immediate release) in a fasting condition
• Tracleer 125Mg Tablet
Single administered dose of Tracleer® (125 mg tablet immediate release) in a fasting condition

Locations

Country	Name	City	State
Russian Federation	Clinical Hospital ? 3	Yaroslavl

Sponsors (1)

Lead Sponsor	Collaborator
Geropharm

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cmax	Pharmacokinetics of bosentan by Assessment of Observed Maximum Plasma Concentration (Cmax)	0 hours (pre-dose), as well as at 0.5, 1, 1.5, 2, 2.5, 3, 3,5, 3,75, 4, 4.25, 4.5, 4.75, 5, 6, 8, 10, 12, 14 and 24 hour post-dose.
Primary	AUC(0-t)	Pharmacokinetics of bosentan by Assessment of Area Under the Curve From Time Zero Extrapolated to "t" (AUC(0-t))	0 hours (pre-dose), as well as at 0.5, 1, 1.5, 2, 2.5, 3, 3,5, 3,75, 4, 4.25, 4.5, 4.75, 5, 6, 8, 10, 12, 14 and 24 hour post-dose.